Showing 1 results for Osteosarcoma.
Samira Naderinezhad, Fateme Haghirosadat , Ghasem Amoabediny , Ali Naderinezhad , Zahra Esmaili , Azim Akbarzade,
Volume 7, Issue 27 (9-2017)
Abstract
Aim and Background:
Osteosarcoma is the most common cancer among adolescents. Curcumin has induction sensitivity effect to cancer cells against chemotherapy and anti-tumor. In present study, the sustained- release niosomal carrier containing Curcumin were prepared to improve anti-cancer effect of Curcumin against osteosarcoma.
Material and methods:
Anionic prepared niosomal vesicle are contained 70 % (molar ratio) of Tween 60, 30% (molar ratio) of Cholesterol in the presence DSPE-mPEG 200. Prepared nano-particle was characterized and the cytotoxicity of free Curcumin was evaluated in comparing of niosomal Curcumin on MG-63 cell line using MTT assay. A suitable kinetic model was also suggested in order to predicting drug release.
Results:
Results showed the size diameter, encapsulation efficiency, zeta potential and poly disparity index are 242 nm, 95.2%, -38 mv and 0.17, respectively. Prepared niosomal particles are controlled-release and the cumulative release is 43.87 % during 96 hours. Peppa’s model indicates good confirmation with experimental results. Cytotoxicity results showed 0.9-fols improvement in killing cells efficiency for niosomal Curcumin in comparing free Curcumin.
Conclusion:
The niosomal carrier containing Curcumin is sustained-release, mono-disperse with high encapsulation efficiency and suitable size diameter. The results of surface charge evaluation confirmed that prepared nano-carrier is anionic and it can effectively be used in the treatment of bone cancer.